ReviewVirulence2024
Pathogenicity and virulence of
Review in Virulence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- An insight into the antibiotic resistance profiles of ESKAPE pathogens isolated from humans in Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Disruption ofVirulence · 2026Article
- Synergetic attenuated inflammatory response and increased apoptosis confer high pathogenicity ofVirulence · 2026Article
- Outbreak of Multidrug-Resistant (MDR) Acinetobacter baumannii ST-15 Strains Co-producing OXA-23 and OXA-58 in South America.Current microbiology · 2026Article
- Review
- Antimicrobial Resistance and Virulence ofAntibiotics (Basel, Switzerland) · 2026Article
- In Vitro Synergistic Effects of Selected Essential Oil Components Against ClinicalMolecules (Basel, Switzerland) · 2026Article
- Clinical Outcomes of Pandrug-Resistant Versus Carbapenem-Resistant, Colistin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Article
- Integrated clinical and genomic characterization ofJournal of medical microbiology · 2026Article
- Rapid identification of carbapenem-resistant Acinetobacter baumannii based on MALDI-TOF mass spectrometry and machine learning.BMC microbiology · 2026Article
- ZnO@TiOMaterials (Basel, Switzerland) · 2026Article
- Contezolid and polymyxin B nonapeptide combination reveals antibacterial synergy against multidrug-resistant Acinetobacter baumannii strains.BMC microbiology · 2026Article
- High-Resolution Genomic Surveillance of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Review
- From Epigenetic Regulation to Protein Degradation: Emerging Strategies for Anti-Infective Drug Discovery.International journal of molecular sciences · 2026Review
- Global multi-host genomic epidemiology of Acinetobacter baumannii reveals transmission at one health interfaces.Nature communications · 2026Article
- Genomic and phenotypic analysis of multidrug-resistant Acinetobacter baumannii focusing on efflux pump activity and biofilm-associated genes.Molecular biology reports · 2026Article
- AbCro, a novel transcription factor, promotes biofilm formation and virulence in Acinetobacter baumannii.BMC microbiology · 2026Article
- A mutation-aware proteomics approach for designing a multi-epitope vaccine against multidrug-resistantMicrobiology spectrum · 2026Article
- New Insights intoPathogens (Basel, Switzerland) · 2026Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.